UNICA IRIS Institutional Research Information System

CARTA, MANOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 191.776
NA - Nord America 8.147
AS - Asia 3.008
SA - Sud America 427
Continente sconosciuto - Info sul continente non disponibili 341
AF - Africa 83
OC - Oceania 9
Totale 203.791
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 190.050
US - Stati Uniti d'America 7.973
SG - Singapore 1.211
CN - Cina 976
UA - Ucraina 376
SE - Svezia 351
BR - Brasile 334
DE - Germania 300
VN - Vietnam 266
FI - Finlandia 170
GB - Regno Unito 166
FR - Francia 149
HK - Hong Kong 106
CA - Canada 92
KR - Corea 89
IN - India 84
NL - Olanda 44
BD - Bangladesh 41
RU - Federazione Russa 38
AR - Argentina 37
IQ - Iraq 36
JP - Giappone 34
ES - Italia 31
MX - Messico 22
TR - Turchia 20
PL - Polonia 18
ID - Indonesia 17
PK - Pakistan 16
SA - Arabia Saudita 16
ZA - Sudafrica 16
BE - Belgio 15
VE - Venezuela 15
CO - Colombia 13
CZ - Repubblica Ceca 13
PH - Filippine 13
AT - Austria 11
EG - Egitto 11
MA - Marocco 11
SC - Seychelles 11
IL - Israele 10
AE - Emirati Arabi Uniti 9
KE - Kenya 9
CR - Costa Rica 8
CW - ???statistics.table.value.countryCode.CW??? 8
JM - Giamaica 8
TT - Trinidad e Tobago 8
GT - Guatemala 7
PE - Perù 7
CH - Svizzera 6
CL - Cile 6
JO - Giordania 6
LT - Lituania 6
NI - Nicaragua 6
PR - Porto Rico 6
PY - Paraguay 6
TH - Thailandia 6
TW - Taiwan 6
AZ - Azerbaigian 5
EC - Ecuador 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
RO - Romania 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
DK - Danimarca 4
HN - Honduras 4
IE - Irlanda 4
LB - Libano 4
NP - Nepal 4
AO - Angola 3
BB - Barbados 3
BO - Bolivia 3
DZ - Algeria 3
GR - Grecia 3
PA - Panama 3
SN - Senegal 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MN - Mongolia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
Totale 203.443
Salva come PNG Salva come JPEG
Città #
Cagliari 178.215
Uta 11.366
Ashburn 823
Fairfield 722
Singapore 623
Woodbridge 554
San Jose 433
Chandler 420
Houston 383
Ann Arbor 306
Boardman 263
Dallas 246
Seattle 246
Wilmington 241
Cambridge 233
Nyköping 206
Beijing 204
Jacksonville 201
Council Bluffs 158
Los Angeles 132
Santa Clara 132
Dearborn 121
The Dalles 105
New York 100
Helsinki 98
Hong Kong 97
Ho Chi Minh City 90
Seoul 88
Hefei 87
Shanghai 82
Nanjing 79
Lauterbourg 72
Hanoi 58
Boston 51
Milan 45
San Diego 45
Buffalo 40
Munich 38
Columbus 34
Phoenix 34
Atlanta 29
Tokyo 29
Guangzhou 28
Rome 27
Orem 26
San Francisco 25
São Paulo 25
Toronto 25
Frankfurt am Main 24
Redwood City 24
Montreal 22
Brooklyn 21
Chicago 21
London 21
Denver 20
Falls Church 20
Shenyang 20
Tianjin 19
Washington 19
Dong Ket 18
Norwalk 18
Redondo Beach 18
Stockholm 17
Carrboro 16
Nuremberg 16
Baghdad 15
Hebei 15
Pisa 15
Verona 15
Chennai 14
Mountain View 14
Sassari 14
Amsterdam 13
Brussels 13
Changsha 13
Da Nang 12
Düsseldorf 12
Jiaxing 12
Orange 12
Mumbai 11
Newark 11
Padova 11
Turku 11
Warsaw 11
Brno 10
Hangzhou 10
Manchester 10
Dhaka 9
Haiphong 9
Nanchang 9
North Bergen 9
Pune 9
San Mateo 9
Zhengzhou 9
Naples 8
Oristano 8
Porto Alegre 8
Riyadh 8
Willemstad 8
Hải Dương 7
Totale 198.403
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson's disease 24.370
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease 7.325
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction 5.864
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats 4.661
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 4.548
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.362
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.312
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 4.100
Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT 1A, but not 5-HT 2 receptor activation 3.762
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? 3.747
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia 3.710
Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats 3.596
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.568
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation 3.492
Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues 3.438
Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine 3.384
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Parkinson's disease: a preliminary finding 3.362
Vitamin A deficiency produces spatial learning and memory impairment in rats 3.289
null 2.940
Biphasic effects of ethanol on acetylcholine release in the rat prefrontal cortex 2.895
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.891
VGF peptides as novel biomarkers in Parkinson’s disease 2.850
Amphetamine usage, misuse, and addiction processes: an overview 2.663
Augmented cocaine-induced accumbal dopamine efflux, motor activity and place preference in rats fed with a tryptophan-deficient diet 2.653
The serotonergic system in levodopa-induced dyskinesia 2.608
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia 2.604
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease 2.598
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding 2.393
Optimization of continuous in vivo DOPA production and studies of ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats 2.392
Startle Reflex as a possible biomarker associated with REM sleep behavior disorders in the prodromal stage of Parkinson's disease 2.361
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration 2.313
null 2.298
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson's Disease 2.290
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease 2.287
Modulation of the Startle Response in REM Sleep Behavior Disorder 2.285
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation 2.265
null 2.247
Foetal cell transplantation for Parkinson's disease: focus on graft-induced dyskinesia 2.216
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations 2.196
Role of serotonin neurons in L-DOPA- and graft-induced dyskinesia in a rat model of parkinson's disease 2.191
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: A correlation study 2.188
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson's disease 2.183
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients 2.038
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats 1.949
Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia 1.811
L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease 1.787
null 1.663
null 1.607
null 1.604
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and5-HT1B receptor agonists in the rat Parkinson model 1.566
null 1.471
Dyskinesia in Parkinson’s disease: a clinical complication and an open scientific question 1.437
BDNF Overexpression Increases Striatal D3Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia 1.430
Role of serotonin neurons in the induction of L-DOPA- and graft-induced dyskinesias in Parkinson´s disease 1.417
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease 1.289
A simple method for large-scale generation of dopamine neurons from human embryonic stem cells 1.271
Nurr1 is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons 1.270
Transcriptome analysis in a rat model of L-dopa-induced dyskinesia 1.268
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update 1.237
Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine 1.128
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.125
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease 1.117
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 1.110
The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons 1.108
Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease 1.054
Vitamin A deficiency affects neither frontocortical acetylcholine nor working memory 996
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia 976
Involvement of the serotonin system in L-DOPA-induced dyskinesias 972
Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats 955
Critical involvement of cAMP/DARPP-32 and ERK signaling in L-DOPA-induced dyskinesia 928
5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model 918
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease 859
Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant miceAberrant accumbal innervation and sensitized motor response to amphetamine in Otx2 conditional mutant mice 849
null 780
Pharmacological validation of a mouse model of L-dopa-induced dyskinesia 765
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression 762
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation 735
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats 716
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy 703
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective 637
null 565
Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration 561
Expanding the therapeutic potential of neuro(active)steroids: a promising strategy for hyperdopaminergic behavioral phenotypes 480
null 475
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy 463
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats 449
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 394
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia 350
null 320
Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease 230
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease 216
The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease 140
Early Dopaminergic Dysfunction Induces PRO-VGF Changes in Blood and Brain of Rats with Alpha-Synuclein Overexpression 117
VGF INVOLVEMENT ON PARKINSON’S DISEASE 26
Totale 203.791
Salva come PNG Salva come JPEG
Categoria #
all - tutte 244.695
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 244.695
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.125 0 0 0 0 526 628 560 320 524 804 895 868
2022/202311.901 930 1.332 1.279 1.047 1.030 1.108 609 966 866 923 1.239 572
2023/202412.436 420 409 385 642 1.139 1.764 1.873 1.101 492 875 1.338 1.998
2024/202578.894 28.757 18.481 23.888 2.526 1.260 1.333 1.590 124 294 205 173 263
2025/20266.500 435 206 568 545 523 472 1.681 362 428 558 457 265
2026/20272.155 177 616 533 768 61 0 0 0 0 0 0 0
Totale 203.791